AI assistant
EXELIXIS, INC. — Director's Dealing 2019
Apr 4, 2019
30561_dirs_2019-04-03_22013145-4963-4a0d-9255-ccd334a66945.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EXELIXIS, INC. (EXEL)
CIK: 0000939767
Period of Report: 2019-04-01
Reporting Person: WYSZOMIERSKI JACK L (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-04-01 | Common Stock | M | 11250 | $4.16 | Acquired | 113031 | Direct |
| 2019-04-01 | Common Stock | M | 15000 | $4.57 | Acquired | 128031 | Direct |
| 2019-04-01 | Common Stock | S | 7822 | $23.97 | Disposed | 120209 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-04-01 | Option (right to buy) | $4.16 | M | 11250 | Disposed | 2019-05-13 | Common Stock (11250.0) | Direct |
| 2019-04-01 | Option (right to buy) | $4.57 | M | 15000 | Disposed | 2019-05-23 | Common Stock (15000.0) | Direct |
Footnotes
F1: Includes 7,937 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018.
F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.88 to $24.12. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4: The option, representing the right to purchase a total of 11,250 shares of Exelixis, Inc. common stock, became fully exercisable on May 14, 2009.
F5: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 24, 2012.